⚠️FOR RESEARCH PURPOSES ONLY
ResearchPeptide

SS-31

Published Research

PubMed-indexed studies for SS-31

Research

Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice.

Journal of neuroinflammation 2019
View on PubMed →
Research

Mitochondria-targeting peptide SS-31 attenuates ferroptosis via inhibition of the p38 MAPK signaling pathway in the hippocampus of epileptic rats.

Brain research 2024
View on PubMed →
Research

SS-31@Fer-1 Alleviates ferroptosis in hypoxia/reoxygenation cardiomyocytes via mitochondrial targeting.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2025
View on PubMed →
Research

Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential.

International journal of molecular sciences 2025
View on PubMed →
Research

The mitochondrially targeted peptide elamipretide (SS-31) improves ADP sensitivity in aged mitochondria by increasing uptake through the adenine nucleotide translocator (ANT).

GeroScience 2023
View on PubMed →
Research

Mitochondria-targeted antioxidant peptide SS-31 mediates neuroprotection in a rat experimental glaucoma model.

Acta biochimica et biophysica Sinica 2019
View on PubMed →
⚠️ For laboratory research only. Not for human use.